Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07RPV
|
|||
| Former ID |
DNC008843
|
|||
| Drug Name |
HALOPEMIDE
|
|||
| Synonyms |
Halopemide; 59831-65-1; UNII-65Q28TV0ZY; R 34,301; MLS003171133; 65Q28TV0ZY; CHEMBL245621; R-34301; N-(2-(4-(5-Chloro-2-oxo-1-benzimidazolinyl)piperidino)ethyl)-p-fluorobenzamide; Halopemida; Halopemidum; Halopemide [USAN:INN]; Halopemidum [INN-Latin]; Halopemida [INN-Spanish]; C21H22ClFN4O2; N-[2-[4-(5-Chloro-2-oxo-1-benzimidazolinyl)piperidino]ethyl]-p-fluorobenzamide; Halopemide, 8; NSC 354856; Halopemide (USAN/INN); AC1L23CG; R 34301; MLS006012046; cid_65490; SCHEMBL121267; Halopemide, > CTK8G0128; AOB5520
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H22ClFN4O2
|
|||
| Canonical SMILES |
C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCNC(=O)C4=CC=C(C=C4)F
|
|||
| InChI |
1S/C21H22ClFN4O2/c22-15-3-6-19-18(13-15)25-21(29)27(19)17-7-10-26(11-8-17)12-9-24-20(28)14-1-4-16(23)5-2-14/h1-6,13,17H,7-12H2,(H,24,28)(H,25,29)
|
|||
| InChIKey |
NBHPRWLFLUBAIE-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 59831-65-1
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phospholipase D (PLD) | Target Info | Inhibitor | [1] |
| Phospholipase D1 (PLD1) | Target Info | Inhibitor | [1] | |
| BioCyc | Phospholipases | |||
| KEGG Pathway | Glycerophospholipid metabolism | |||
| Ether lipid metabolism | ||||
| Metabolic pathways | ||||
| Ras signaling pathway | ||||
| cAMP signaling pathway | ||||
| Sphingolipid signaling pathway | ||||
| Endocytosis | ||||
| Fc gamma R-mediated phagocytosis | ||||
| Glutamatergic synapse | ||||
| GnRH signaling pathway | ||||
| Pathways in cancer | ||||
| Pancreatic cancer | ||||
| Choline metabolism in cancer | ||||
| Panther Pathway | Angiogenesis | |||
| Ras Pathway | ||||
| Pathway Interaction Database | RhoA signaling pathway | |||
| Arf6 trafficking events | ||||
| CDC42 signaling events | ||||
| Arf6 downstream pathway | ||||
| mTOR signaling pathway | ||||
| ErbB1 downstream signaling | ||||
| IL8- and CXCR1-mediated signaling events | ||||
| Alpha-synuclein signaling | ||||
| Reactome | Role of phospholipids in phagocytosis | |||
| WikiPathways | EGF/EGFR Signaling Pathway | |||
| TSH signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009 Feb;5(2):108-17. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.